Porchia Barbara Rita, Bonanni Paolo, Bechini Angela, Bonaccorsi Gugliemo, Boccalini Sara
a School of Specialization in Hygiene and Preventive Medicine , University of Florence , Florence , Italy.
b Department of Health Sciences , University of Florence , Florence , Italy.
Expert Rev Vaccines. 2017 Feb;16(2):93-107. doi: 10.1080/14760584.2017.1242419. Epub 2016 Oct 12.
Pneumococcal infection is a public health concern that disproportionately affects the young, the elderly, and the immunocompromised. There is an open debate on the implementation of polysaccharide and/or conjugate vaccines for pneumococcal diseases in adults and the elderly in many countries. The aim of this paper is to systematically review the economic profile of pneumococcal vaccines in adults in terms of costs and benefits. Areas covered: The search for economic studies on pneumococcal vaccination was carried out in Pubmed, Embase, Scopus, and the HTA and NHS EED databases and through a manual search in journals dealing with economic evaluations. We included original articles and reviews with economic evaluation of polysaccharide 23-valent (PPV23) and/or conjugate pneumococcal vaccine 13-valent (PCV13) use in adults, the elderly, and at-risk groups to provide a systematic review of economical evaluation. Expert commentary: Pneumococcal vaccination is strongly recommended for all adults, especially subjects at risk and the elderly. Pneumococcal vaccination with PCV13 or PPV23 in adults is good value for money and should be a priority for the decision-makers. The main issue is how vaccination could be offered.
肺炎球菌感染是一个公共卫生问题，对年轻人、老年人和免疫功能低下者的影响尤为严重。在许多国家，关于在成人和老年人中实施肺炎球菌疾病多糖疫苗和/或结合疫苗存在公开辩论。本文旨在从成本和效益方面系统地综述成人肺炎球菌疫苗的经济概况。涵盖领域：在PubMed、Embase、Scopus以及卫生技术评估（HTA）和英国国家卫生服务经济评价数据库（NHS EED）中检索关于肺炎球菌疫苗接种的经济研究，并通过在涉及经济评估的期刊中进行手动检索。我们纳入了对多糖23价（PPV23）和/或13价结合肺炎球菌疫苗（PCV13）在成人、老年人和高危人群中使用进行经济评估的原创文章和综述，以提供经济评估的系统综述。专家评论：强烈建议所有成年人接种肺炎球菌疫苗，尤其是高危人群和老年人。成人接种PCV13或PPV23肺炎球菌疫苗性价比高，应成为决策者的优先选择。主要问题是如何提供疫苗接种。
